Antiviral Activity of Tannic Acid Modified Silver Nanoparticles: Potential to Activate Immune Response in Herpes Genitalis

Orłowski, Piotr; Kowalczyk, Andrzej; Tomaszewska, Emilia; Ranoszek-Soliwoda, Katarzyna; Węgrzyn, Agnieszka; Grzesiak, Jakub; Celichowski, Grzegorz; Grobelny, Jarosław; Eriksson, Kristina; Krzyżowska, Małgorzata

doi:10.3390/v10100524

Cited by 103 publications

(82 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The TA-mediated AgNP-treated group also showed significantly increased percentages of IFN-gamma+ CD8+ T-cells, activated B cells and plasma cells, while the spleens contained significantly higher percentages of IFN-gamma+ NK cells and effector-memory CD8+ T cells compared to NaCl-treated group. Further, the AgNP-treated animals showed significantly better sera titers of anti-HSV-2 neutralization antibodies than the NaCl-treated animals [83]. AgNPs interaction with HIV-1 in size-dependent manner and that the bound particles exhibit regular spatial relationships.…”

Section: Silver Nanoparticlesmentioning

confidence: 85%

Antiviral Potential of Nanoparticles—Can Nanoparticles Fight Against Coronaviruses?

et al. 2020

View full text Add to dashboard Cite

Infectious diseases account for more than 20% of global mortality and viruses are responsible for about one-third of these deaths. Highly infectious viral diseases such as severe acute respiratory (SARS), Middle East respiratory syndrome (MERS) and coronavirus disease (COVID-19) are emerging more frequently and their worldwide spread poses a serious threat to human health and the global economy. The current COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of 27 July 2020, SARS-CoV-2 has infected over 16 million people and led to the death of more than 652,434 individuals as on 27 July 2020 while also causing significant economic losses. To date, there are no vaccines or specific antiviral drugs to prevent or treat COVID-19. Hence, it is necessary to accelerate the development of antiviral drugs and vaccines to help mitigate this pandemic. Non-Conventional antiviral agents must also be considered and exploited. In this regard, nanoparticles can be used as antiviral agents for the treatment of various viral infections. The use of nanoparticles provides an interesting opportunity for the development of novel antiviral therapies with a low probability of developing drug resistance compared to conventional chemical-based antiviral therapies. In this review, we first discuss viral mechanisms of entry into host cells and then we detail the major and important types of nanomaterials that could be used as antiviral agents. These nanomaterials include silver, gold, quantum dots, organic nanoparticles, liposomes, dendrimers and polymers. Further, we consider antiviral mechanisms, the effects of nanoparticles on coronaviruses and therapeutic approaches of nanoparticles. Finally, we provide our perspective on the future of nanoparticles in the fight against viral infections.

show abstract

Section: Silver Nanoparticlesmentioning

confidence: 85%

Antiviral Potential of Nanoparticles—Can Nanoparticles Fight Against Coronaviruses?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In addition, nanoparticles possess intrinsic antiviral activity as it could be produced to have biomimetic features. A well-known example of this property is silver nanoparticles that have been shown to possess antiviral activity against HBV, HIV, and influenza virus [127,128]. Also, gold nanoparticles have demonstrated substantial virucidal activity against the measles virus presenting them as a possible candidate for the prevention and treatment of enveloped viruses [129].…”

Section: Resveratrolmentioning

confidence: 99%

Targeting arachidonic acid–related metabolites in COVID-19 patients: potential use of drug-loaded nanoparticles

Shoieb,

El-Ghiaty,

El-Kadi

2020

emergent mater.

View full text Add to dashboard Cite

In March 2020, The World Health Organization (WHO) has declared that the coronavirus disease 2019 (COVID-19) is characterized as a global pandemic. As of September 2020, infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to 213 countries and territories around the world, affected more than 31.5 million people, and caused more than 970,000 deaths worldwide. Although COVID-19 is a respiratory illness that mainly targets the lungs, it is currently well established that it is a multifactorial disease that affects other extra-pulmonary systems and strongly associated with a detrimental inflammatory response. Evidence has shown that SARS-CoV-2 causes perturbation in the arachidonic acid (AA) metabolic pathways; this disruption could lead to an imbalance between the pro-inflammatory metabolites of AA including mid-chain HETEs and terminal HETE (20-HETE) and the anti-inflammatory metabolites such as EETs and subterminal HETEs. Therefore, we propose novel therapeutic strategies to modulate the level of endogenous anti-inflammatory metabolites of AA and induce the patient’s endogenous resolution mechanisms that will ameliorate the virus-associated systemic inflammation and enhance the primary outcomes in COVID-19 patients. Also, we propose that using nanoencapsulation of AA and its associated metabolites will contribute to the development of safer and more efficacious treatments for the management of COVID-19.

show abstract

“…Tannic acid (TA) is a compound found in different species of plants, but its structure varies according to their sources. It previously demonstrated antiviral activity against viruses as Herpes (HSV) and HCV [48,49]. The anti-CHIKV activity of TA was investigated by KONISHI and HOTTA by performing plaque reduction assay using BHK-21 cells [50].…”

Section: Tannic Acidmentioning

confidence: 99%

Antivirals Against Chikungunya Virus: Is the Solution in Nature?

Martins

Santos

Oliveira

et al. 2020

Viruses

View full text Add to dashboard Cite

The worldwide outbreaks of the chikungunya virus (CHIKV) in the last years demonstrated the need for studies to screen antivirals against CHIKV. The virus was first isolated in Tanzania in 1952 and was responsible for outbreaks in Africa and Southwest Asia in subsequent years. Between 2007 and 2014, some cases were documented in Europe and America. The infection is associated with low rates of death; however, it can progress to a chronic disease characterized by severe arthralgias in infected patients. This infection is also associated with Guillain-Barré syndrome. There is no specific antivirus against CHIKV. Treatment of infected patients is palliative and based on analgesics and non-steroidal anti-inflammatory drugs to reduce arthralgias. Several natural molecules have been described as antiviruses against viruses such as dengue, yellow fever, hepatitis C, and influenza. This review aims to summarize the natural compounds that have demonstrated antiviral activity against chikungunya virus in vitro.Viruses 2020, 12, 272 2 of 17 CHIKV belongs to the Alphavirus genus and the Togaviridae family. It is a positive-sense, single-stranded RNA (12 kb in length) virus, with an enveloped icosahedral capsid [10]. The virus lifecycle starts via the attachment of the viral glycoproteins to the cell membrane receptors, mainly to MXRA8 [11,12] but also to prohibitin (PHB) [13], phosphatidylserine (PtdSer) [14], and glycosaminoglycans (GAGs) [15] receptors in mammalian and to ATP synthase β in mosquito cells [16], forming a pore. Then, a virus capsid is released into the cytoplasm, where the replication process takes place. Viral genome is uncoated and directly translated into nonstructural (NS) proteins nP1-4. The NS proteins form the viral replicase complex that catalyzes the synthesis of a negative strand, a template to synthesize the full-length positive sense genome, and the subgenomic mRNA. The subgenomic mRNA is translated in a polyprotein, which is cleaved to produce the structural proteins C, E3, E2, 6k, and E1, followed by the assembly of the viral components and virus release (Figure 1) [17,18].

show abstract

Antiviral Activity of Tannic Acid Modified Silver Nanoparticles: Potential to Activate Immune Response in Herpes Genitalis

Cited by 103 publications

References 45 publications

Antiviral Potential of Nanoparticles—Can Nanoparticles Fight Against Coronaviruses?

Antiviral Potential of Nanoparticles—Can Nanoparticles Fight Against Coronaviruses?

Targeting arachidonic acid–related metabolites in COVID-19 patients: potential use of drug-loaded nanoparticles

Antivirals Against Chikungunya Virus: Is the Solution in Nature?

Contact Info

Product

Resources

About